Literature DB >> 21946777

Coronary artery disease: Dalcetrapib safely raises HDL-cholesterol level in the phase IIb dal-PLAQUE trial.

Gregory B Lim.   

Abstract

Entities:  

Year:  2011        PMID： 21946777     DOI： 10.1038/nrcardio.2011.150

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  1 in total

1.  Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial.

Authors:  Zahi A Fayad; Venkatesh Mani; Mark Woodward; David Kallend; Markus Abt; Tracy Burgess; Valentin Fuster; Christie M Ballantyne; Evan A Stein; Jean-Claude Tardif; James H F Rudd; Michael E Farkouh; Ahmed Tawakol
Journal:  Lancet       Date:  2011-09-09       Impact factor: 79.321
  1 in total
  1 in total

1.  Control of hypercholesterolemia and atherosclerosis using the cholesterol recognition/interaction amino acid sequence of the translocator protein TSPO.

Authors:  Laurent Lecanu; Zhi-Xing Yao; Althea McCourty; El-Khansa Sidahmed; Maria E Orellana; Miguel N Burnier; Vassilios Papadopoulos
Journal:  Steroids       Date:  2012-11-23       Impact factor: 2.668
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.